ProfileGDS5678 / 1442060_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 66% 64% 64% 63% 64% 68% 68% 65% 63% 64% 64% 64% 66% 65% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0490266
GSM967853U87-EV human glioblastoma xenograft - Control 23.8551664
GSM967854U87-EV human glioblastoma xenograft - Control 33.8573464
GSM967855U87-EV human glioblastoma xenograft - Control 43.7190963
GSM967856U87-EV human glioblastoma xenograft - Control 53.7698564
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1818968
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.1697968
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.8908765
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7958363
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7981864
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8669164
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7809664
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9843166
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8695765